AltruBio

PRODUCT PIPELINE

• Product
  Indication

  • Preclinical
  • Phase I
  • Phase IIa
  • Phase IIb
  • Phase III
• Immunology Product - PSGL1:T-Cell Checkpoint Regulator Platform

• ALTB-268

  Ulcerative Colitis

  • PRECLINICAL

  • PHASE I

  • PHASE IIA

  • PHASE IIB

  • PHASE III

  • MARKET

  Phase II Potency improved version of ALTB-168, Phase 1 trial in healthy volunteers completed. Ph2a trial in UC patients initiated in late 2023.

  Psoriatic Arthritis

  • PRECLINICAL

  • PHASE I

  • PHASE IIA

  • PHASE IIB

  • PHASE III

  • MARKET

  Preclinical Promising phase 2a results have been obtained with ALTB-168. With the same binding domains present on ALTB-268, phase 2a study of PsA of ALTB-268 is under planning.

• ALTB-168

  Psoriasis, Psoriatic Arthritis, Ulcerative Colitis

  • PRECLINICAL

  • PHASE I

  • PHASE IIA

  • PHASE IIB

  • PHASE III

  • MARKET

  Phase II Phase 2 Psoriasis trials completed with signs of clinical efficacy achieved.
  Phase 2a Psoriatic Arthritis (PsA) and Phase 2a Ulcerative Colitis (UC) trials completed with signs of clinical efficacy demonstrated.
  UC and PsA development continued with ALTB-268.

  Acute Graft vs. Host Disease

  • PRECLINICAL

  • PHASE I

  • PHASE IIA

  • PHASE IIB

  • PHASE III

  • MARKET

  Phase I Phase 1 investigator-sponsored front line acute graft versus host disease trial ongoing.
  Phase 1b multi-dose steroid/treatment refractory acute graft versus host disease trial completed with sign of clinical efficacy.